Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Revive Therapeutics Ltd announces positive pre-clinical results for Rett Syndrome


Wednesday, 14 May 2014 07:30am EDT 

Revive Therapeutics Ltd:Says positive results from a pre-clinical study with tianeptine for the treatment of Rett syndrome, a rare disease (referred to by Revive as 'REV-003'). 

Company Quote

0.5
 --
20 Aug 2015